Clinical Research Submission

Last Modified: 7/8/2025, 3:54:14 PM

1. Administration

Name of Research Principal: Dr.PPoonam Baral

Department: Clinical Pharmacology and Therapeutics

Study Title: Knowledge, Attitude and Practices of caregivers in diarrheal diseases of under 5

children with special reference to the use of medications

Review Requested: Full Committee Review

Submission Date: 7/8/2025

Submitted At: 7/8/2025, 6:02:22 AM

Version Number: 01 Date: 6/30/2025

Protocol Number: AB12 Employee code: 51046

Summary:

Selected Elements:

Other Reason:

2. Investigators

Researchers

Name: Dr.Poonam Baral

Designation: Senior resident Qualification: MBBS MD

Department: Clinical Pharmacology and Therapeutics

Investigator Type: Principal Investigator

Employee code: 51046

Alternate Gmail: drpoonambaral@gmail.com

Contact: 9937840937

Name: Dr.Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Abinash Panda

Designation: Associate professor

Qualification: MBBS MD

Department: Pharmacology Investigator Type: Guide Employee code: 51046

Alternate Gmail: drabinashpanda@gmail.com

Contact: 9874563452

,

Name: Dr.JAYANTI Prava Behera

Designation: PROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY

Investigator Type: hod Employee code: 51046

Alternate Gmail: drjayanti12@gmail.com

Contact: 9987879986

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

,

Name: Dr. Ansuman Abhisekh

Designation: ASSISTANT PPROFESSOR

Qualification: MBBS MD

Department: PHARMACOLOGY Investigator Type: Co-investigator

Employee code: 51046

Alternate Gmail: dransuman34@gmail.com

Contact: 9987899876

Funding Details

Funding Source: self-funding

Total Estimated Budget: ₹ 50000

Proposed Budget: ₹ 50000 Cost Per Patient: ₹ 50

Total Project Cost: ₹ 50000

NIMS Investigations:

• Name: CYP 3A4 Study

Cost: 500

Is Outsourced: Yes

Outsourced

Investigations:

• Name:

Cost:

Lab:

NABL:

Overview of the Research

Summary: To study the genetic profile of patients on warfarin

Type of Study: cross-sectional

Other Study Type: null

External Laboratory Involved: No

Specify (if External Lab):

Justification: To simplify drug dosing

Sample Size: 50

Employee code: 51046

Participants

Type of Participants: patient Specify (if applicable): N/A

Justification:

Additional Safeguards:
Reimbursement Details:
Advertisement Details:
Payment Type: No.

Payment Type: No

Advertisement Type: No Employee code: 51046 Vulnerable Groups:

Benefits Details

Reimbursement Details:

Risk Management Strategy:

Anticipated Type of Benefits: No

Participant Benefits: Indirect Society Benefits: Indirect

Improvement Benefits: Direct

Employee code: 51046

Consent Details

Seeking Waiver of Consent Type: No

Specify:

Employee code: 51046 Version Number: 01

Date: 7/8/2025 Subject: No

Certificates: No

Selected Languages: Telugu

Telugu

Version: cpt/tel Date: 7/8/2025

PIS Selected Items:

- Statement that study involves research & explain purpose of research
- Statement that consent & participation are voluntary
- Expected Risks and benefits to the study subject
- Alternatives procedures / therapies available
- Contact information of PI and Member Secretary of EC
- Financial compensation and medical management in SAE
- Right to withdraw from study at any time
- Expected duration of participation
- Maintenance of Confidentiality
- · Responsibility of subject

Summary:

Waiver Selected Elements:

Compensation & Payment Details

Waiver of Consent Type: NA

Specify: hksfhkshf

Compensation for Research-Related Injury: NA

Specific Compensation Details: fhskhfksfh

Employee code: 51046

Storage and Access Details

Control Details: documents will be kept under lock and key

Access Details:

Sample Access Type: Yes Sample Details: Unidentified Document Access Type: Yes

Drugs Access Type: NA Employee code: 51046

null

Additional Support Information

Support Type: No Additional Details:

Employee code: 51046

Declaration

Selected Declarations:

- • I/We certify that the information provided in this application is complete and correct.
- I/We confirm that all investigators have approved the submitted version of proposal /related documents
- I/We confirm that this study will be conducted in accordance with the latest ICMR National Ethical Guidelines for Biomedical and Health Research involving HumanParticipants and other applicable regulations and guidelines including responsible
- I/We will comply with all policies and guidelines of the institute and affiliated / collaborating institutions wherever applicable
- I/We confirm that we shall submit any protocol amendments, adverse events
 report, significant deviations from protocols, regular progress reports and a final report
 and also participate in any audit of the study if needed
- I/We confirm that we will maintain accurate and complete records of all aspects of the study.
- • I/We will protect the privacy of participants and assure safety and confidentiality of study data and biological samples.

Principal Investigator: Dr. Poonam Baral

Date: 7/8/2025

Signature: poonam

<>

Co-PI / Guide: Dr. Padmaja

Date: 7/8/2025

Signature: Padmaja

<>

HOD: Dr. P Usharani

Date: 7/8/2025

Signature: Usharani

14. Checklist

	Q
Cover letter enlisting all documents enclosed	View File
Assent form for minors (12-18 years)	File: null
MOU between collaborating partners	File: null
EC clearance of other centers	File: null
Participant Information Sheet (PIS) and Informed Consent Form (ICF)	
Brief CV of all Investigators (updated, signed and dated)	
Good Clinical Practice (GCP) training of investigators in last 3 years	View File
CRF / Interview guides / Focused Group Discussions (English and translated)	
Copy of the detailed protocol (clearly identified numbered and dated) and synopsis	View File
Advertisement / material to recruit participants	File: null
Insurance policy / participant coverage details	File: null